Biogen shares slide 4% after EU advisory committee says it can't agree to endorse company's Alzheimer's disease drug

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 97%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

EU advisory committee says it can't endorse Biogen Alzheimer's-disease drug

Biogen Inc. shares BIIB, -3.78% slid 4% in premarket trade Wednesday, after the company said it had received a"negative trend vote" from an advisory committee to the European Medicines Agency for its Alzheimer's disease treatment aducanumab. The vote means that the committee was unable to agree to grant authorization to the treatment, which has already won approval from the U.S. Food and Drug Administration, in a decision deemed controversial.

"While we are disappointed with the trend vote, we strongly believe in the strength of our data and that aducanumab has the potential to make a positive and meaningful difference for people and families affected by Alzheimer's disease," said Priya Singhal, M.D., M.P.H., head of global safety & regulatory sciences and interim head of R&D at Biogen.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Biden even has a Alzheimer Disease drug? Cool

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 3. in BR

Brasil Últimas Notícias, Brasil Manchetes